News & Events about Pardes Biosciences Inc.
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies ("SPACs"): Skillsoft Corp. f/k/a Churchill Capital Corporation II (NYSE: SKIL), OppFi Inc. ...
SAN DIEGO, Jan. 14, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies ("SPACs"): Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II (NYSE: KIND), ...
Ticker Report
2 months ago
Pardes Biosciences, Inc. (NASDAQ:PRDS Get Rating) Equities research analysts at SVB Leerink lifted their FY2024 EPS estimates for shares of Pardes Biosciences in a report issued on Monday, November 7th. SVB Leerink analyst R. Ruiz now forecasts that the company will post earnings per...
Globe Newswire
4 months ago
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and ...
Pardes Biosciences (NASDAQ:PRDS Get Rating) had its price target dropped by investment analysts at SVB Leerink from $18.00 to $12.00 in a research report issued on Tuesday, MarketBeat.com reports. The firm presently has an outperform rating on the stock. SVB Leerinks price objective indicates a ...